Refine your search
Collections
Journals
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
J. Patel, Devanshu
- Anti-BPH Activity of Polyherbal Formulation on Testosterone Induced Benign Prostatic Hyperplasia in Rats
Abstract Views :90 |
PDF Views:70
Authors
Affiliations
1 Department of Pharmacology, L.M. College of Pharmacy, Ahmedabad - 380009, Gujarat, IN
2 Vasu Research Center (A Division of Vasu Healthcare Pvt. Ltd.), G.I.D.C., Makarpura, Vadodara - 390010, IN
3 Department of Pharmacology, Parul Institute of Medical Science and Research, Parul University, Limda, Waghodia, Vadodara - 391760, Gujarat, IN
4 Department of Pharmacology, Parul Institute of Pharmacy and Research, Parul University, Vadodara, Gujarat - 391760, IN
1 Department of Pharmacology, L.M. College of Pharmacy, Ahmedabad - 380009, Gujarat, IN
2 Vasu Research Center (A Division of Vasu Healthcare Pvt. Ltd.), G.I.D.C., Makarpura, Vadodara - 390010, IN
3 Department of Pharmacology, Parul Institute of Medical Science and Research, Parul University, Limda, Waghodia, Vadodara - 391760, Gujarat, IN
4 Department of Pharmacology, Parul Institute of Pharmacy and Research, Parul University, Vadodara, Gujarat - 391760, IN
Source
Journal of Natural Remedies, Vol 22, No 4 (2022), Pagination: 617-627Abstract
Benign prostatic hyperplasia (BPH) is an enlargement of the prostate gland caused by progressive hyperplasia, or abnormal growth of cells of the glandular epithelial and stromal cells. Globally, it has been documented that more than 80% of men by the age of 80 will suffer from BPH. Most men are hesitant to undergo surgical interventions for fear of losing potency and the perception of other adverse side effects. Effectto® is a polyherbal formulation designed by Vasu Research Center to be used for the treatment of BPH. It can also be indicated that it can be used for lower urinary tract symptoms and bladder outlet obstruction. The formulation is expected to provide significant BPH relief. The present study was planned to evaluate the effect of a polyherbal formulation on testosterone- and citral-induced Prostatic Hyperplasia. The activity of the polyherbal formulation for BPH was evaluated using testosterone depot injection as the inducing agent in a testosterone-induced model and citral-induced model for the atypical type of BPH in rats. Also, the acute toxicity study was done using OECD 423 guidelines to check the toxicity of the test compound. Data are expressed as mean ± SD and statistical significance was evaluated using one way ANOVA followed by Tukey’s multiple comparison tests. The polyherbal formulation was found to be safe at oral doses of 2000 mg/kg. Effectto® significantly decreased the weight of the prostate in the testosterone model as well as the citral model in rats. The effect on biochemical markers like serum PSA and TNF-α was also seen in both the cases. In particular serum PSA, the decrease was majorly significant in both the models when XIII compared. The formulation was able to reverse the effect of inducing agents on the prostate’s size.Keywords
Benign Prostatic Hyperplasia, Citral, Effectto®, Finasteride, LUTS, PSA, Testosterone.Full Text
References
- Roehrborn C. Benign Prostatic Hyperplasia: An Overview. Rev Urol. 2005; 7(9):S3-S14.
- Alan C, Kirilmaz B, Koçoglu H, et al. Comparison of effects of alpha receptor blockers on endothelial functions and coagulation parameters in patients with benign prostatic hyperplasia. Prostatic diseases and male voiding dysfunction. Urol. 2011; 77:1439-43.https://doi.org/10.1016/j. urology.2010.10.019 DOI: https://doi.org/10.1016/j.urology.2010.10.019
- Abrams P. In support of pressure-flow studies for evaluating men with lower urinary tract symptoms. Urol. 1994; 44:4153- 155.https://doi.org/10.1016/S0090-4295(94)80119-3 DOI: https://doi.org/10.1016/S0090-4295(94)80119-3
- Patel N and Parsons K. Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction Indian. J Urol. 2014; 30(2):170-176.https://doi.org/10.4103/0970- 1591.126900 DOI: https://doi.org/10.4103/0970-1591.126900
- McVary K. BPH: epidemiology and comorbidities. Am J Manag Care. 2006; 12(5):122-128.
- Miller J, Tarter T. Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate. [J]. Clin Interv Aging. 2009; 4:251-258.https://doi. org/10.2147/CIA.S4102 DOI: https://doi.org/10.2147/CIA.S4102
- Keong T. Diagnosis and treatment of benign prostate hyperplasia in Asia. Transl Androl Urol. 2015; 4(4):478-483.
- Gonzalez R, Kaplan S. First-line treatment for symptomatic benign prostatic hyperplasia: Is there a particular patient profile for a particular treatment? World J Urol. 2006; 24:360-6.https://doi.org/10.1007/s00345-006-0092-0 DOI: https://doi.org/10.1007/s00345-006-0092-0
- Henry B, Parwani A. Atypical adenomatous hyperplasia (adenosis) of the prostate: a case report with review of the literature. Diagn Pathol. 2008; 3(34).https://doi. org/10.1186/1746-1596-3-34 DOI: https://doi.org/10.1186/1746-1596-3-34
- Nahata A, Dixit V. Ameliorative effects of stinging nettle (Urtica dioica) on testosterone-induced prostatic hyperplasia in rats. Andrologia. 2012; 44(11):396–409. https://doi.org/10.1111/j.1439-0272.2011.01197.x DOI: https://doi.org/10.1111/j.1439-0272.2011.01197.x
- Ramani R, Panigrahy B, Sahu S, et al. Effect of menthe piperita in experimental Prostatic hyperplasia in Wistar albino rats. Int J Pharm Pharm Sci. 2014; 7(2).
- Barffour I, Boye A, Ernest A, et al. Histoprotective Effect of Essential oil from Citrus aurantifolia in Testosterone- Induced Benign Prostatic Hyperplasia. Rat Adv Uro. 2019. https://doi.org/10.1155/2019/3031609 DOI: https://doi.org/10.1155/2019/3031609
- Instruction Manual, the quantitative determination of Rat PSA concentration. https://www.genxbio.com/rat_elisa.html
- Instruction Manual, the quantitative determination of Rat TNF-α conc. https://www.raybiotech.com/ rat-tumor-necrosis-factor-alpha-elisa-kit-forserumplasma- and-cell-culture-supernatant/